Notice: Function amp_is_available was called incorrectly. `amp_is_available()` (or `amp_is_request()`, formerly `is_amp_endpoint()`) was called too early and so it will not work properly. WordPress is currently doing the `init` hook. Calling this function before the `wp` action means it will not have access to `WP_Query` and the queried object to determine if it is an AMP response, thus neither the `amp_skip_post()` filter nor the AMP enabled toggle will be considered. It appears the plugin with slug `jetpack` is responsible; please contact the author. Please see Debugging in WordPress for more information. (This message was added in version 2.0.0.) in /var/www/wp-includes/functions.php on line 5835
fixed dose combination – Force Pharma Capital
Skip to content
Force Pharma Capital
Force Pharma Capital
Life Science Consulting, Business Development and Recruiting/Staffing
  • Home
  • About Us
  • Services
  • Pharmaceutical Blog
    • RLD
    • Excipients
    • Equipment
    • Health Technology
    • Regulatory Fees
  • Contact Us
  • FAQ
  • Portfolio

Tag: fixed dose combination

Channel in Nerve Cell May be Key in Unlocking Parkinson Disease Therapy

December 3, 2019 Blogger

Researchers have identified a channel in nerve cells that may serve as a new approach to targeting Parkinson disease. —…

Continue Reading →

Posted in: Health Technology Filed under: fixed dose combination, technology

FDA Announces Availability of Draft Guidance – Type V DMFs for CDER-Led Combination Products Using Device Constituent Parts with Electronics or Software

October 28, 2019 Blogger

FDA Announces Availability of Draft Guidance – Type V DMFs for CDER-Led Combination Products Using Device Constituent Parts with Electronics…

Continue Reading →

Posted in: Health Technology Filed under: FDA, fixed dose combination

FDA approves new breakthrough therapy for cystic fibrosis | FDA

October 21, 2019 Blogger

FDA approves breakthrough therapy Trikafta for patients 12 and older with cystic fibrosis who have at least one F508del mutation…

Continue Reading →

Posted in: Health Technology Filed under: approvals, FDA, fixed dose combination, pdufa, technology

Treating Pancreatic Cancer by Altering the Tumor Microbiome – National Cancer Institute

October 1, 2019 Blogger

In people with pancreatic cancer, the composition of their tumor microbiome might predict how long they live, according to a…

Continue Reading →

Posted in: Health Technology Filed under: fixed dose combination

Molecular basis of dengue virus serotype 2 morphological switch from 29°C to 37°C

September 22, 2019 Blogger

Molecular basis of dengue virus serotype 2 morphological switch from 29°C to 37°C — Read on journals.plos.org/plospathogens/article

Continue Reading →

Posted in: Health Technology Filed under: fixed dose combination, pdufa

NIH to investigate minor cannabinoids and terpenes for potential pain-relieving properties | National Institutes of Health (NIH)

September 21, 2019 Blogger

Despite a lack of robust evidence, cannabinoids—such as CBD—are often assumed to be safe and effective. — Read on www.nih.gov/news-events/news-releases/nih-investigate-minor-cannabinoids-terpenes-potential-pain-relieving-properties

Continue Reading →

Posted in: Health Technology Filed under: FDA, fixed dose combination

Mayo researchers demonstrate senescent cell burden is reduced in humans by senolytic drugs – Mayo Clinic News Network

September 19, 2019 Blogger

Mayo researchers demonstrate senescent cell burden is reduced in humans by senolytic drugs — Read on newsnetwork.mayoclinic.org/discussion/mayo-researchers-demonstrate-senescent-cell-burden-is-reduced-in-humans-by-senolytic-drugs/

Continue Reading →

Posted in: Health Technology Filed under: FDA, fixed dose combination, pdufa

Two-Pronged Approach Shows Promise as Effective Treatment Option in AML

September 12, 2019 Blogger

A new study identified pathways that may serve as therapeutic targets for overcoming drug resistance in acute myeloid leukemia. —…

Continue Reading →

Posted in: Health Technology Filed under: fixed dose combination, pdufa

Ilixadencel/Sunitinib Combo Therapy Achieves Positive Results in Metastatic Renal Cell Cancer

September 9, 2019 Blogger

Results from a phase 2 study demonstrated complete tumor responses in patients with metastatic renal cell carcinoma treated with the…

Continue Reading →

Posted in: Health Technology Filed under: fixed dose combination, puffs

First hint that body’s ‘biological age’ can be reversed

September 8, 2019 Blogger

In a small trial, a cocktail of drugs seemed to rejuvenate the body’s ‘epigenetic clock’. — Read on www.nature.com/articles/d41586-019-02638-w Another…

Continue Reading →

Posted in: Health Technology Filed under: fixed dose combination, pdufa

Post navigation

Page 1 of 2
1 2 Next →

Recent Posts

  • Most Recent Changes to the IID Database | FDA
  • The History, Benefits of Pharmaceutical REMS Programs
  • FDA approves first drug for treatment of peanut allergy for children

Recent Comments

  • flower bouquet delivery online on FDA Grants Priority Review to Zanubrutinib for Relapsed/Refractory Mantle Cell Lymphoma
  • cheap flowers online same day delivery on Trending News Today: Investigational Long-Acting HIV Injection Shows Efficacy in Study
  • flower arrangements for baby shower girl on FDA Grants Priority Review to Zanubrutinib for Relapsed/Refractory Mantle Cell Lymphoma

Archives

  • August 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • November 2018

Follow Us

Contact Us

  • Email
    forcepharma@icloud.com
  • Phone
    732-702-1824
  • Address
    265 Route 34 Lower Level, Colts Neck, New Jersey, 07722
Copyright © 2018 Force Pharma Capital